Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + carmustine + cytarabine + carboplatin
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
**Cyclophosphamide + carmustine + cytarabine + carboplatin** (also known as CECC) is a multi-agent chemotherapy combination regimen consisting of four cytotoxic agents: cyclophosphamide (alkylating agent), carmustine (nitrosourea alkylating agent), cytarabine (antimetabolite pyrimidine analog), and carboplatin (platinum-based alkylating-like agent). It is primarily used in high-dose settings as a conditioning regimen prior to autologous stem cell transplantation for relapsed or refractory lymphomas, such as Hodgkin lymphoma and non-Hodgkin lymphoma. The regimen leverages synergistic DNA damage and inhibition of DNA synthesis to eradicate malignant cells, though it carries significant risks of myelosuppression, pulmonary toxicity (from carmustine), and other chemotherapy-related toxicities.
- Other names
- CECC
02
Targets
DNA polymerase familyDNA
Beyond the preview
Go deeper on cyclophosphamide + carmustine + cytarabine + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + carmustine + cytarabine + carboplatin.